8.3
Farmacocinetica non lineare: equazione di Michaelis-Menten
L'equazione di Michaelis-Menten è un modello fondamentale per descrivere la cinetica a capacità limitata nel metabolismo dei farmaci. Offre informazio…
L'equazione di Michaelis-Menten descrive la cinetica a capacità limitata nel metabolismo dei farmaci.
Determina il tasso di declino della concentrazione del farmaco nel tempo, con Vmax e KM come parametri chiave.
Vmax è la velocità massima di processo, mentre KM, la costante di Michaelis, mostra la concentrazione del farmaco a metà di questa velocità massima.
Si verificano tre scenari basati sulla relazione tra KM e Cp, la concentrazione plasmatica del farmaco.
Quando KM è uguale a Cp, la velocità di processo è la metà del suo massimo.
Quando KM è maggiore di Cp, la velocità di processo imita l'eliminazione di primo ordine tipicamente nella maggior parte dei farmaci a livelli terapeutici.
Quando KM è minore di Cp, il processo mantiene una velocità costante, simile all'eliminazione di ordine zero. Alcuni farmaci come i salicilati e la fenitoina, a dosi terapeutiche elevate, saturano le ossidasi epatiche a funzione mista, seguendo una cinetica di ordine zero.
Il grafico di Michaelis-Menten mostra un aumento iniziale della velocità lineare con la concentrazione, passando all'ordine misto a concentrazioni più elevate e infine raggiungendo un plateau a Vmax.
View the full transcript and gain access to JoVE Core videos
Q1: What do Vmax and KM represent in the Michaelis-Menten equation?
Vmax is the maximum process rate at which drug metabolism occurs, representing the saturation point of metabolic enzymes. KM, the Michaelis constant, indicates the drug concentration at which the process rate reaches half its maximum value. Together, these parameters define the capacity-limited kinetics of drug elimination.
Q2: How does drug concentration affect elimination rate in nonlinear pharmacokinetics?
When drug concentration (Cp) is much lower than KM, elimination follows first-order kinetics, with rate proportional to concentration. As Cp approaches and exceeds KM, kinetics transition to mixed-order, then zero-order elimination at high concentrations. At zero-order, the elimination rate becomes constant and independent of drug concentration.
Q3: Why do certain drugs like phenytoin and salicylates show different kinetics at higher doses?
At therapeutic doses, phenytoin and salicylates follow first-order elimination. However, at elevated doses, these drugs saturate hepatic mixed-function oxidases, the enzymes responsible for their metabolism. This saturation shifts their kinetics to zero-order elimination, where the metabolic rate plateaus regardless of further dose increases.
Q4: What does the Michaelis-Menten plot reveal about drug metabolism?
The Michaelis-Menten plot illustrates how elimination rate changes with drug concentration. It shows an initial linear increase at low concentrations, transitions to mixed-order kinetics at intermediate concentrations, and reaches a plateau at Vmax. This graphical representation demonstrates the shift from first-order to zero-order elimination patterns.
Q5: What is the relationship between KM, Cp, and process rate?
When KM equals Cp, the process rate operates at exactly half its maximum capacity. If KM exceeds Cp, the process mimics first-order elimination typical of most drugs at therapeutic levels. Conversely, when KM is less than Cp, the process maintains a constant rate similar to zero-order elimination.
Q6: How does capacity-limited kinetics differ from linear drug elimination?
Capacity-limited kinetics, described by the Michaelis-Menten equation, accounts for enzyme saturation during drug metabolism. Unlike linear first-order kinetics where elimination rate is always proportional to concentration, capacity-limited kinetics show variable elimination rates depending on whether metabolic enzymes are saturated or unsaturated.
Q7: When does the Michaelis-Menten equation apply to drug metabolism?
The Michaelis-Menten equation applies when drug metabolism is limited by enzyme capacity rather than drug availability. This occurs particularly with drugs that saturate hepatic enzymes at therapeutic or elevated doses. Understanding when this equation applies helps predict how elimination rate changes across different dose ranges and plasma concentrations.